124 related articles for article (PubMed ID: 22916600)
1. [CROI 2012: updates on raltegravir].
MMW Fortschr Med; 2012 May; 154 Suppl 1():41. PubMed ID: 22916600
[No Abstract] [Full Text] [Related]
2. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
Vispo E; Mena A; Maida I; Blanco F; Cordoba M; Labarga P; Rodriguez-Novoa S; Alvarez E; Jimenez-Nacher I; Soriano V
J Antimicrob Chemother; 2010 Mar; 65(3):543-7. PubMed ID: 20032006
[TBL] [Abstract][Full Text] [Related]
3. FDA notifications. FDA grants approval for raltegravir.
AIDS Alert; 2009 Apr; 24(4):46-8. PubMed ID: 19382366
[No Abstract] [Full Text] [Related]
4. Liver tolerance of raltegravir-containing antiretroviral therapy in HIV-infected patients with chronic hepatitis C.
Macías J; Neukam K; Portilla J; Iribarren JA; de Los Santos I; Rivero A; Márquez M; Delgado M; Téllez F; Merino D; Giner L; von Wichmann MA; Pineda JA;
J Antimicrob Chemother; 2011 Jun; 66(6):1346-50. PubMed ID: 21398295
[TBL] [Abstract][Full Text] [Related]
5. [Integrase inhibition].
Bogner JR
MMW Fortschr Med; 2009 Apr; 151(18):68-71. PubMed ID: 19769082
[No Abstract] [Full Text] [Related]
6. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
7. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients.
AIDS Alert; 2009 Sep; 24(9):106-7. PubMed ID: 19938313
[No Abstract] [Full Text] [Related]
8. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic strategies for raltegravir.
Garrido C; Soriano V; de Mendoza C
J Antimicrob Chemother; 2010 Feb; 65(2):218-23. PubMed ID: 20016017
[TBL] [Abstract][Full Text] [Related]
10. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
Burger DM
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
[TBL] [Abstract][Full Text] [Related]
11. Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient.
Di Biagio A; Rosso R; Siccardi M; D'Avolio A; Bonora S; Viscoli C
J Antimicrob Chemother; 2009 Oct; 64(4):874-5. PubMed ID: 19643773
[No Abstract] [Full Text] [Related]
12. Raltegravir: the first HIV type 1 integrase inhibitor.
Hicks C; Gulick RM
Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
[TBL] [Abstract][Full Text] [Related]
13. Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.
Boyle BA; Cohen CJ; DeJesus E; Elion R; Frank I; Moyle GJ; Sax PE
AIDS Read; 2009 Apr; 19(4):158-60. PubMed ID: 19388184
[No Abstract] [Full Text] [Related]
14. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
[TBL] [Abstract][Full Text] [Related]
15. [Integrase inhibition--a new mode of action in HIV therapy].
van Lunzen J; Degen O
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():64-7. PubMed ID: 19031567
[No Abstract] [Full Text] [Related]
16. [Long-term therapy strategy with raltegravir. Appropriate in all illness phases].
Warpakowski A
MMW Fortschr Med; 2011 May; 153(18):50-1. PubMed ID: 21604599
[No Abstract] [Full Text] [Related]
17. [Treatment of chronic hepatitis B].
Mauss S
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():48-51. PubMed ID: 19031564
[No Abstract] [Full Text] [Related]
18. Role of raltegravir in HIV-1 management.
Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of chronic hepatitis C in patients with HIV coinfection: efficacy and tolerance].
Pol S
Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B264-73. PubMed ID: 12180300
[No Abstract] [Full Text] [Related]
20. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
TreatmentUpdate; 2009; 21(3):3-4. PubMed ID: 19623725
[No Abstract] [Full Text] [Related]
[Next] [New Search]
